TNFSF13B and systemic lupus erythematosus: Belimumab, the first biological agent approved for the treatment of SLE, is a monoclonal antibody that targets B cell activating factor (BAFF)/B lymphocyte stimulator (BLyS) therefore suppressing B cell activation and maturation [15].